Operon Biotechnologies, through a partnership with DNA2.0, has entered the gene synthesis market, a growing application area for oligonucleotides.
DNA2.0 and Operon Biotechnologies will combine their technologies and product lines. The companies believe that adding Operon's oligonucleotide production platform to DNA2.0's gene-synthesis process will increase the speed of synthesis. Operon will co-market DNA2.0's gene-synthesis services.
“Construction of synthetic genes requires oligos of only the highest quality,” remarks Jeremy Minshull, president of DNA2.0. “Operon's fully automated oligo-synthesis process meets our exacting quality requirements and their speed and responsiveness makes Operon an outstanding partner for DNA2.0 in the gene-synthesis marketplace.”